Retatrutide activates three, targeting GLP-1, GIP, and glucagon receptors simultaneously, which is why Eli Lilly calls it a "triple agonist." This triple mechanism is also why the dose schedule matters more than with any other weight loss peptide on the market
Retrieved from Ankar, A., Kumar A
An oral product avoids injection-site pain, bruising and the low risk of anaphylaxis
While microdosing can be highly advantageous, its important to acknowledge its primary drawback: it may delay the achievement of initial therapeutic results as it takes longer to reach the effective dose
If the product or dispensing pharmacy permits BAC water with Sodium Chloride (NaCl), the salt addresses tonicity rather than acidity
The company has committed 432 million (~$506M) to upgrade and retrofit its Athlone, Ireland facility to manufacture oral GLP-1 medicines including the Wegovy pill